Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05041322
Other study ID # 2016P002409
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 29, 2020
Est. completion date November 29, 2024

Study information

Verified date February 2023
Source Spaulding Rehabilitation Hospital
Contact Glen Picard, MA
Phone 617-758-5511
Email gpicard@partners.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to find out if taking the drug Buspar will increase breathing capacity in individuals with spinal cord injuries.


Description:

Chemoreceptive regulatory feedback is crucial for precise ventilatory control, especially during exercise. However, individuals with high-level SCI have a reduced chemoreceptive drive to breathe. Studies have shown lesser increases in minute ventilation and mouth pressure during hypercapnia in those with tetraplegia. Peripheral factors rather than central factors appear to cause the reduction of the ventilatory response to hypercapnia. This reduced ventilatory drive may have functional impact on exercise ventilation in patients with high level SCI and enhancing ventilatory drive may improve exercise ventilation in high-level SCI. Currently, there are no treatments to overcome these functional deficits that affect daily activity and exercise-based rehabilitation recovery. However, previous work in an animal model of SCI has found that that a serotonin agonist markedly increases respiratory responses to carbon dioxide. Treatment with a serotonin 5HT1A agonist effectively improved the ventilatory drive after both acute and chronic spinal cord injuries in rats. One potential mechanism is increased excitability of the ventral motoneurons that have survived the spinal cord injury. 5-HT1A receptors do exist on these neurons, and when activated, amplify the excitatory output. Another mechanism resides at the intercostal and abdominal muscle afferents which influence supraspinal respiratory group neurons in the brainstem and motor output to the muscles of breathing. Hence, serotonin agonists may act on neural pathways in the spinal cord responsible for transferring afferent information from intercostal muscles to supraspinal centers. Lastly, 5-HT1A receptors may also be involved in functional plasticity of neural respiratory pathways, in particular ipsilateral phrenic nerve activity. Up regulation of 5-HT1A receptors due to denervation supersensitivity could result in postsynaptic hyperresponsivity due to loss of descending input. BuSpar/Buspirone is a serotonin 5HT1A agonist and used as an anxiolytic in humans. It does not cause sedation, has minimal effects on psychomotor performance or cognition, and has low threshold for abuse potential or dependence liability. Prior studies have found Buspirone to be well tolerated. It has been used safely in spinal cord injury, but not for respiratory purposes. (Though there is one clinical trial in process: Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients with SCI.) However, Buspirone up to 60 mg daily has been used to treat disturbed respiratory rhythms in multiple sclerosis, brain cancer, and brainstem infarction. Interestingly, in patients with COPD, a 14-day oral administration of buspirone (20 mg) found improved anxiety and depression as well as increased exercise tolerance with lesser sensations of dyspnea. Hence, buspirone may offer a treatment to improve hypercapnic ventilatory drive. Given that oral administration of 30 mg results in peak plasma levels at one hour and that the average elimination half life is about 2 to 3 hours, buspirone is an attractive and safe approach to exploring the ability to improve respiratory responses to exercise and/or hypercapnia exposure in those with high level spinal cord injury that limits breathing capacity.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date November 29, 2024
Est. primary completion date November 29, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Chronic high-level SCI (at least 24-months post injury) - Age 18 to 50 years. - Medically stable - Spinal Cord Injury =T3 - American Spinal Injury Association grade A or B or C. - Able to perform arm crank exercise. Exclusion Criteria: - Cardiomyopathy - High blood pressure( >140/90 mmHg or you are taking high blood pressure medication) - Significant irregular heartbeat - Heart disease - Chronic lung disease (COPD, bronchitis) - Current use of cardioactive or antidepressant drugs - Family history of significant irregular heart beat or sudden cardiac death - Orthostatic hypotension (symptomatic fall in blood pressure >30 mmHg when upright) - Current grade 2 or greater pressure ulcers at relevant contact site - Neurological disease (stroke, peripheral neuropathy, myopathy) - Arm or shoulder conditions that limit ability to perform arm crank exercise - History of bleeding disorder, diabetes, kidney disease, cancer, other neurological disease - Recent weigh change (greater than 10 pounds) - Regular use of tobacco - Intrathecal baclofen pump, - Current use of cardioactive, antidepressant, other sedating agents - Suicidal ideation - Pregnant and/or breastfeeding women. In addition, subjects must have no known hypersensitivity to Buspar and must not be taking a monoamine oxidase inhibitor.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Buspirone
Subjects take 30 mg buspirone HCl (15 mg twice a day) for 14 Days.
Placebo
Subjects take placebo pills (twice a day) for 14 Days.

Locations

Country Name City State
United States Spaulding Hospital Cambridge Cambridge Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Spaulding Rehabilitation Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pulmonary Function A change in FEV1 14 Days
Primary Hypercapnic Ventilatory Response A change in the drive to breathe with a change in carbon dioxide 14 Days
Primary Sleep Quality A change in sleep apneas 14 Days
Primary Exercise Pulmonary Capacity Change in peak oxygen consumption during exercise 14 Days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06321172 - Muscle and Bone Changes After 6 Months of FES Cycling N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05484557 - Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury N/A
Suspended NCT05542238 - The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Not yet recruiting NCT05506657 - Early Intervention to Promote Return to Work for People With Spinal Cord Injury N/A
Recruiting NCT03680872 - Restoring Motor and Sensory Hand Function in Tetraplegia Using a Neural Bypass System N/A
Recruiting NCT04105114 - Transformation of Paralysis to Stepping Early Phase 1
Completed NCT04221373 - Exoskeletal-Assisted Walking in SCI Acute Inpatient Rehabilitation N/A
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Completed NCT03898700 - Coaching for Caregivers of Children With Spinal Cord Injury N/A
Recruiting NCT04883463 - Neuromodulation to Improve Respiratory Function in Cervical Spinal Cord Injury N/A
Active, not recruiting NCT04881565 - Losing Balance to Prevent Falls After Spinal Cord Injury (RBT+FES) N/A
Completed NCT04864262 - Photovoice for Spinal Cord Injury to Prevent Falls N/A
Recruiting NCT04007380 - Psychosocial, Cognitive, and Behavioral Consequences of Sleep-disordered Breathing After SCI N/A
Active, not recruiting NCT04544761 - Resilience in Persons Following Spinal Cord Injury
Completed NCT03220451 - Use of Adhesive Elastic Taping for the Therapy of Medium/Severe Pressure Ulcers in Spinal Cord Injured Patients N/A
Terminated NCT03170557 - Randomized Comparative Trial for Persistent Pain in Spinal Cord Injury: Acupuncture vs Aspecific Needle Skin Stimulation N/A
Recruiting NCT04811235 - Optical Monitoring With Near-Infrared Spectroscopy for Spinal Cord Injury Trial N/A
Recruiting NCT04736849 - Epidural and Dorsal Root Stimulation in Humans With Spinal Cord Injury N/A